Clinical Trial Results:
            Efficacy and safety of 3 doses (0.25, 0.5 and 1mg/day) of agomelatine sublingual administration over an 8-week treatment period, in out-patients with Major Depressive Disorder. 
An 8-week randomised, double-blind, fixed dose, international multicentre, placebo-controlled study with parallel groups, followed by an extension double-blind treatment period of 16 weeks.
    
| 
                 Summary 
         | 
        |
    EudraCT number  | 
        2009-014045-92 | 
    Trial protocol  | 
        FI FR CZ SE EE | 
    Global completion date  | 
        
                                    01 Sep 2011
                             
         | 
    
| 
                 Paediatric regulatory details 
         | 
        |
    Is the trial part of an agreed EMA paediatric investigation plan?  | 
        
                                        No
                                 
         | 
    
    Is the trial in scope of article 45 of Regulation (EC) No 1901/2006?  | 
        
                                        No
                                 
         | 
    
    Is the trial in scope of article 46 of Regulation (EC) No 1901/2006?  | 
        
                                        No
                                 
         | 
    
| 
                 Results information 
         | 
        |
    Results version number  | 
        v1(current) | 
    This version publication date  | 
        
                                    10 Dec 2016
                             
         | 
    
    First version publication date  | 
        
                                    10 Dec 2016
                             
         | 
    
    Other versions  | 
        |
    Summary report(s)  | 
                                Synopsis dated on 04-September-2012 | 
    
            Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to            Commission Guideline 2012/C 302/03
            for further information.